Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, has announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that its lead drug candidate, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, conducted under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. The results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma, which shares many biological similarities with the human disease.
Osteosarcoma is a type of bone cancer that affects both humans and dogs, with limited treatment options and poor prognosis in advanced cases. The finding that Telomir-Zn can inhibit growth in both species' cell lines at low concentrations suggests a possible dual-purpose therapeutic strategy. Canine osteosarcoma occurs naturally in dogs and often mirrors the progression and genetic alterations seen in human osteosarcoma, making it a valuable model for developing new treatments. If successful, this approach could accelerate the development of therapies for human patients while also providing a new option for veterinary medicine.
Telomir is currently in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. However, the company emphasized that its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic triple-negative breast cancer. Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation, targeting pathways implicated in cancer.
For investors and industry observers, this news highlights Telomir's expanding pipeline beyond its lead breast cancer program. The ability to demonstrate efficacy in multiple cancer models could open additional licensing or partnership opportunities and attract interest from both human and veterinary oncology sectors. The potential to repurpose a drug candidate for both human and animal health is a growing trend in biotechnology, as it can reduce development costs and timelines by leveraging overlapping biological mechanisms. Moreover, the successful development of a canine osteosarcoma treatment could provide a compassionate use pathway for pets while generating valuable data for human trials.
The announcement also underscores the importance of academic-industry collaborations in advancing early-stage research. By working with a leading veterinary institution like The Ohio State University College of Veterinary Medicine, Telomir can access specialized expertise and resources that might not be available internally. The full press release can be viewed at https://nnw.fm/laeGH. For ongoing updates on Telomir Pharmaceuticals, the company's newsroom is available at https://nnw.fm/TELO.
While the results are preliminary and further studies are needed, the findings represent a promising step forward in the search for new osteosarcoma treatments. If Telomir-Zn continues to show efficacy in more advanced models, it could eventually offer a new therapeutic option for a disease that has seen few advancements in recent decades. The company's next steps, including the potential in vivo study, will be closely watched by investors and the medical community alike.
